AAVL

Avalanche Biotechnologies

Healthcare


Presented:02/27/2015
Price:$36.18
Cap:$0.89B
Current Price:$7.69
Cap:$0.16B

Presented

Date02/27/2015
Price$36.18
Market Cap$0.89B
Ent Value$0.72B
P/E RatioN/A
Book Value$6.93
Div YieldN/A
Shares O/S24.48M
Ave Daily Vol2,130,000
Short Int5.17%

Current

Price$7.69
Market Cap$0.16B
Avalanche Biotechnologies, Inc., a clinical-stage biotechnology company, focuses on discovering and developing novel gene therapies for the treatment of ophthalmic diseases based on its Ocular BioFactory platform. Its lead product candidate includes AVA-101, which is in a Phase I/IIa trial for the treatment of wet age-related macular degeneration (AMD). The company is also developing AVA-201, an anti-vascular endothelial growth factor gene therapy product candidate for the prevention of wet AMD; and AVA-311 that is in preclinical studies for the treatment of juvenile X-linked retinoschisis, a rare genetic disease of the retina with no approved therapy. Avalanche Biotechnologies, Inc. has a collaboration agreement with Regeneron Pharmaceuticals, Inc. research, develop, and commercialize gene therapy products. The company was founded in 2006 and is headquartered in Menlo Park, California.

Publicly traded companies mentioned herein: Avalanche Biotechnologies Inc (AAVL), Ophthotech Corp (OPHT), Regeneron Pharmaceuticals (REGN), Spark Therapeutics Inc (ONCE)

Highlights

The presenter is long shares of Avalanche Biotechnologies (AAVL), and thinks shares are attractively valued in the mid-$30s. The company is a pure play in the ophthalmology segment of the market, and is a leader in gene therapy for age-related macular degeneration (AMD). Shares have fallen from $60 in January (2015) following the announcement of a 2 million share offering, but this created an attractive buying opportunity, in the presenter’s opinion, as the AMD market is a $10 billion market.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.